PD-L1 expression in nonclear-cell renal cell carcinoma

T. K. Choueiri, A. P. Fay, K. P. Gray, M. Callea, Thai H Ho, L. Albiges, J. Bellmunt, J. Song, I. Carvo, M. Lampron, M. L. Stanton, F. S. Hodi, D. F. McDermott, M. B. Atkins, G. J. Freeman, M. S. Hirsch, S. Signoretti

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Background: Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Results: Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P =0.01) and grade (P= 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P =0.02 and P=0.03, respectively). Conclusion: In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.

Original languageEnglish (US)
Pages (from-to)2178-2184
Number of pages7
JournalAnnals of Oncology
Volume25
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Renal Cell Carcinoma
Ligands
Neoplasms
Cell Membrane
Survival
Staining and Labeling
Recurrence
Paraffin
Formaldehyde
Immunohistochemistry

Keywords

  • Benign kidney tumors
  • Immunotherapy
  • Nonclear-cell renal cell carcinoma
  • PD-1 inhibitors
  • PD-L1
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology

Cite this

Choueiri, T. K., Fay, A. P., Gray, K. P., Callea, M., Ho, T. H., Albiges, L., ... Signoretti, S. (2014). PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology, 25(11), 2178-2184. https://doi.org/10.1093/annonc/mdu445

PD-L1 expression in nonclear-cell renal cell carcinoma. / Choueiri, T. K.; Fay, A. P.; Gray, K. P.; Callea, M.; Ho, Thai H; Albiges, L.; Bellmunt, J.; Song, J.; Carvo, I.; Lampron, M.; Stanton, M. L.; Hodi, F. S.; McDermott, D. F.; Atkins, M. B.; Freeman, G. J.; Hirsch, M. S.; Signoretti, S.

In: Annals of Oncology, Vol. 25, No. 11, 01.11.2014, p. 2178-2184.

Research output: Contribution to journalArticle

Choueiri, TK, Fay, AP, Gray, KP, Callea, M, Ho, TH, Albiges, L, Bellmunt, J, Song, J, Carvo, I, Lampron, M, Stanton, ML, Hodi, FS, McDermott, DF, Atkins, MB, Freeman, GJ, Hirsch, MS & Signoretti, S 2014, 'PD-L1 expression in nonclear-cell renal cell carcinoma', Annals of Oncology, vol. 25, no. 11, pp. 2178-2184. https://doi.org/10.1093/annonc/mdu445
Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology. 2014 Nov 1;25(11):2178-2184. https://doi.org/10.1093/annonc/mdu445
Choueiri, T. K. ; Fay, A. P. ; Gray, K. P. ; Callea, M. ; Ho, Thai H ; Albiges, L. ; Bellmunt, J. ; Song, J. ; Carvo, I. ; Lampron, M. ; Stanton, M. L. ; Hodi, F. S. ; McDermott, D. F. ; Atkins, M. B. ; Freeman, G. J. ; Hirsch, M. S. ; Signoretti, S. / PD-L1 expression in nonclear-cell renal cell carcinoma. In: Annals of Oncology. 2014 ; Vol. 25, No. 11. pp. 2178-2184.
@article{546fbccaab2841d884398a80fd88e0a2,
title = "PD-L1 expression in nonclear-cell renal cell carcinoma",
abstract = "Background: Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5{\%} tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Results: Among 101 patients, 11 (10.9{\%}) were considered PD-L1+ in tumor cells: 2/36 (5.6{\%}) of chromophobe RCC, 5/50 (10{\%}) of papillary RCC, 3/10 (30{\%}) of Xp11.2 translocation RCC and 1/5 (20{\%}) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P =0.01) and grade (P= 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4{\%}) patients: 13/36 (36.1{\%}) of chromophobe RCC, 30/50 (60{\%}) of papillary RCC, 9/10 (90{\%}) of Xp11.2 translocation RCC and 5/5 (100{\%}) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P =0.02 and P=0.03, respectively). Conclusion: In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.",
keywords = "Benign kidney tumors, Immunotherapy, Nonclear-cell renal cell carcinoma, PD-1 inhibitors, PD-L1, Renal cell carcinoma",
author = "Choueiri, {T. K.} and Fay, {A. P.} and Gray, {K. P.} and M. Callea and Ho, {Thai H} and L. Albiges and J. Bellmunt and J. Song and I. Carvo and M. Lampron and Stanton, {M. L.} and Hodi, {F. S.} and McDermott, {D. F.} and Atkins, {M. B.} and Freeman, {G. J.} and Hirsch, {M. S.} and S. Signoretti",
year = "2014",
month = "11",
day = "1",
doi = "10.1093/annonc/mdu445",
language = "English (US)",
volume = "25",
pages = "2178--2184",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - PD-L1 expression in nonclear-cell renal cell carcinoma

AU - Choueiri, T. K.

AU - Fay, A. P.

AU - Gray, K. P.

AU - Callea, M.

AU - Ho, Thai H

AU - Albiges, L.

AU - Bellmunt, J.

AU - Song, J.

AU - Carvo, I.

AU - Lampron, M.

AU - Stanton, M. L.

AU - Hodi, F. S.

AU - McDermott, D. F.

AU - Atkins, M. B.

AU - Freeman, G. J.

AU - Hirsch, M. S.

AU - Signoretti, S.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Results: Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P =0.01) and grade (P= 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P =0.02 and P=0.03, respectively). Conclusion: In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.

AB - Background: Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Results: Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P =0.01) and grade (P= 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P =0.02 and P=0.03, respectively). Conclusion: In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.

KW - Benign kidney tumors

KW - Immunotherapy

KW - Nonclear-cell renal cell carcinoma

KW - PD-1 inhibitors

KW - PD-L1

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84984919880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984919880&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu445

DO - 10.1093/annonc/mdu445

M3 - Article

C2 - 25193987

AN - SCOPUS:84984919880

VL - 25

SP - 2178

EP - 2184

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -